Moreover, during anti-tumor immunotherapy, it has been shown that USP7 inhibition causes PD-L1 increased level (119) and IL-10 downregulation by attenuating Treg function (120), which may contribute to enhancing the therapeutic effect of PD-L1 treatment. Here, IL10 is linked to neoplasm.